Analyst Expectations for Karuna Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Karuna Therapeutics (NASDAQ:KRTX) has received mostly bullish ratings from analysts in the last quarter. In the last 3 months, 6 analysts have offered 12-month price targets for Karuna Therapeutics, with an average price target of $257.83, a 12.7% decrease from the previous average price target of $295.33.
November 03, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karuna Therapeutics has received mostly bullish ratings from analysts, but the average price target has decreased by 12.7%.
The news is directly about Karuna Therapeutics and its analyst ratings. While the ratings are mostly bullish, the decrease in the average price target could indicate a potential slowdown in the stock's growth, which could impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100